Nexalin Technology, Inc. announced on February 28, 2025, that patient recruitment has begun for the University of California, San Diego (UCSD) clinical trial. This study evaluates the treatment of mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military personnel and the civilian population.
This milestone follows the successful Institutional Review Board (IRB) approval and pilot testing of Nexalin’s Halo technology at UCSD. The first shipment of HALO™ Clarity devices has been received by UCSD, and these devices are integrated with Nexalin’s app-controlled remote monitoring system.
The study will evaluate Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, which delivers non-invasive deep-brain stimulation. CEO Mark White stated that this is a crucial step in demonstrating the transformative potential of DIFS technology for those affected by mTBI and PTSD, moving closer to making non-invasive deep brain stimulation an accessible solution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.